Barry Cohen

Barry Cohen

Barry Cohen has nearly 30 years in communications and marketing, the majority in senior positions at three large international health care companies – Abbott Laboratories, Warner-Lambert (now part of Pfizer) and Bayer, Inc.

At Abbott, Cohen was a member of the company’s investor relations team, responsible for preparing all financial analyst presentations. He also oversaw the company’s award-winning annual and quarterly reports and was responsible for both the company’s investor seminar and annual shareholders’ meeting.

After relocating to Arizona, Cohen served as editor of M.D. News, a magazine for Phoenix-area physicians. Later he was a reporter for a weekly newspaper in a north Phoenix, where he specialized in business articles and profiles of local publicly traded companies.

To further his knowledge and understanding of financial markets, Cohen earned a series 7 broker’s license and was employed at Charles Schwab as a registered representative.  He returned to the communications field with CPRi Communications, where he wrote numerous case studies and bylined articles for the company’s clients in the health care information technology industry. Later, he worked for a Scottsdale, Ariz.-based investment bank preparing profiles of companies being offered for sale.

Recent Articles

Overreacting to a Prostate Cancer Drug?

Medivation shares are soaring on positive test results. But investors may be getting ahead of reality here.

Amylin Gets a Boost From Its Diabetes Drug Approval

FDA approval of Bydureon -- a once-a-week injectable drug -- could make Amylin a takeover target for a Big Pharma.

Someone Has to Crunch All That Clinical Trial Data

That's where a slew of info-tech companies, ranging from giant Oracle to tiny BioClinica, come in. However, investing is them is no slam dunk.

Small Patient Population? Charge $400K a Year for Your Drug

Companies like BioMarin Pharmaceutical are cashing in on rare diseases, where they can charge hundreds of thousands of dollars every year for their drugs.

Roche’s Hostile Bid for Illumina Could Reach $60 Per Share

Swiss health care giant Roche made a hostile bid to buy Illumina for $44.50 per share, but many think that number will be higher when all is said and done.